|
Post by broncolife on May 31, 2017 12:31:55 GMT -5
If you look at all the dots let's take them one at a time. This is only a theory so take it as such!
1) Mike C. Gets hired to see if Afrezza is salvageable. He works out most of the kinks devolps some key partnerships and some key personalities, while amassing a sales force on MNKD's dime. This is important to remember for later!
2)More Amgen employees get hired in key roles
3)Sanofi settlement
4)Sale of HQ
5)HQ moving closer to Amgen which is a leased facility
6)Mike becomes CEO!
7)MNKD can now be purchased with an operational sales force, better insurance coverage,a CEO with knowledge of the entire operation, a vault full of patents, drugs in the pipeline waiting on cash,and the two most important pieces are left a cheap share price and remember I said on MNKD's dime earlier, which equals a boat load of NOL (Net Operating Loss) credit.
There are more dots than these but my time is constrained. I am a MNKD long for full disclosure. This is strictly for theoretical purposes and conversation. It is not intended to solicit buyers or sellers for MNKD securities.
|
|
|
Post by madog365 on May 31, 2017 12:42:58 GMT -5
I hate the Amgen theory. Not because i wouldn't love Amgen to buy MNKD but because there is NOTHING factual linking Amgen in any way to wanting to purchase Mannkind. The only valid point is that there are now multiple former Amgen employees working for Mannkind. That is it. People move around the industry all the time and it does not mean the company is interested in a buy out.
Pushing this false and speculative narrative takes away from everything else positive that Mannkind has going on. Let it go people, it's doing more harm than good.
|
|
|
Post by broncolife on May 31, 2017 12:46:23 GMT -5
I hate the Amgen theory. Not because i wouldn't love Amgen to buy MNKD but because there is NOTHING factual linking Amgen in any way to wanting to purchase Mannkind. The only valid point is that there are now multiple former Amgen employees working for Mannkind. That is it. People move around the industry all the time and it does not mean the company is interested in a buy out. Pushing this false and speculative narrative takes away from everything else positive that Mannkind has going on. Let it go people, it's doing more harm than good. You did notice I put it was only a theory for conversation. I enjoyed your response!
|
|
|
Post by madog365 on May 31, 2017 12:48:20 GMT -5
Sorry! Not calling you out specifically, it's a common theory that's pushed by people on this board and off of it. Just adding my 2cents. My point is let's focus on on all of the positives that are happening right now! Patients are reporting incredible results, doctors and insurance companies finally coming on board, we have a new CEO who wants to experiment with an innovative DTC distribution model, we have well known diabetic thought leaders spreading the word on their own time and dime, we have a new partner in one drop, a well respected diabetes tech company, We are in final stage negotiations for ex-us distribution, we are actually starting DTC ads on TV next month and a sponsorship of a brand new diabetes reality show, and last but certainly not least - script count seems to be rising
|
|
|
Post by markado on May 31, 2017 12:52:08 GMT -5
I agree it is a possibility. There was something telling in some of the very first comments MC made when coming on board - something to the effect that he'd been watching MNKD for a while. Either way, his advocacy in the marketplace is desperately needed. I just hope he can raise the funds needed to raise the roof and the pps!
|
|
|
Post by broncolife on May 31, 2017 12:58:33 GMT -5
Sorry! Not calling you out specifically, it's a common theory that's pushed by people on this board and off of it. Just adding my 2cents. My point is let's focus on on all of the positives that are happening right now! I did not take it that way. I was soliciting responses good or bad. However if you go back and research AMGN's buyout of Onyx there are some similarities.
|
|
|
Post by kbrion77 on May 31, 2017 13:02:03 GMT -5
If you look at all the dots let's take them one at a time. This is only a theory so take it as such! 1) Mike C. Gets hired to see if Afrezza is salvageable. He works out most of the kinks devolps some key partnerships and some key personalities, while amassing a sales force on MNKD's dime. This is important to remember for later! 2)More Amgen employees get hired in key roles 3)Sanofi settlement 4)Sale of HQ 5)HQ moving closer to Amgen which is a leased facility 6)Mike becomes CEO! 7)MNKD can now be purchased with an operational sales force, better insurance coverage,a CEO with knowledge of the entire operation, a vault full of patents, drugs in the pipeline waiting on cash,and the two most important pieces are left a cheap share price and remember I said on MNKD's dime earlier, which equals a boat load of NOL (Net Operating Loss) credit.There are more dots than these but my time is constrained. I am a MNKD long for full disclosure. This is strictly for theoretical purposes and conversation. It is not intended to solicit buyers or sellers for MNKD securities. The product is not selling. If somebody wanted to buy this company on the cheap it would have happened already. The only runway right now is any type of international deal which again probably would have already happened or a massive round of dilution. Your post is almost identical to all the posts on "dots lining up with Sanofi" not far after the partnership was announced.
|
|
|
Post by babaoriley on May 31, 2017 13:04:20 GMT -5
Bronco, I don't think your theory is so far fetched. It's fetched, at worst, nice job.
|
|
|
Post by brotherm1 on May 31, 2017 13:15:52 GMT -5
As long is it can prove to be commercially responsive it will be noticed by larger companies. Mike recently said they wanted to be sure it is and he said it is.
|
|
|
Post by broncolife on May 31, 2017 14:21:17 GMT -5
If you look at all the dots let's take them one at a time. This is only a theory so take it as such! 1) Mike C. Gets hired to see if Afrezza is salvageable. He works out most of the kinks devolps some key partnerships and some key personalities, while amassing a sales force on MNKD's dime. This is important to remember for later! 2)More Amgen employees get hired in key roles 3)Sanofi settlement 4)Sale of HQ 5)HQ moving closer to Amgen which is a leased facility 6)Mike becomes CEO! 7)MNKD can now be purchased with an operational sales force, better insurance coverage,a CEO with knowledge of the entire operation, a vault full of patents, drugs in the pipeline waiting on cash,and the two most important pieces are left a cheap share price and remember I said on MNKD's dime earlier, which equals a boat load of NOL (Net Operating Loss) credit.There are more dots than these but my time is constrained. I am a MNKD long for full disclosure. This is strictly for theoretical purposes and conversation. It is not intended to solicit buyers or sellers for MNKD securities. The product is not selling. If somebody wanted to buy this company on the cheap it would have happened already. The only runway right now is any type of international deal which again probably would have already happened or a massive round of dilution. Your post is almost identical to all the posts on "dots lining up with Sanofi" not far after the partnership was announced. I do know someone else did a post, but I wanted to add a little clarity. Also I don't buy into the product not selling camp. You have to understand MNKD mgmt. made some mistakes and while they do have a sales force it is small and very focused. Money is currently tight, but if you don't have a Diabetes portfolio, but you do have the cash and sales force to put behind it, plus the carry forward NOL, and not to mention a lot of the wrinkles have been ironed out for you by someone you know personally, then why not?
|
|
|
Post by broncolife on May 31, 2017 14:22:57 GMT -5
Bronco, I don't think your theory is so far fetched. It's fetched, at worst, nice job. It is "fetched" but thanks for taking the time to reply.
|
|
|
Post by sophie on May 31, 2017 14:59:36 GMT -5
Does a company with as deep of pockets as Amgen has entrust such a large asset to an unproven, inexperienced CEO, especially when they could probably go out and pick a better one?
|
|
|
Post by broncolife on May 31, 2017 15:13:36 GMT -5
Does a company with as deep of pockets as Amgen has entrust such a large asset to an unproven, inexperienced CEO, especially when they could probably go out and pick a better one? Thanks for your response! I find it to be a bit illogical in it's rationale however. Let's take your point piece by piece. Mike is now the CEO, he is inexperienced at that position, but he is not an unknown commodity to AMGN or Pharmacueticals. Second he might or might not remain as the CEO depending on how they label MNKD after the acquisition. Again thanks for the input.
|
|
|
Post by sportsrancho on May 31, 2017 16:31:06 GMT -5
Matt successfully set the foundation for the company during its transition into a commercial entity and effectively prepared Michael to be his successor.” Mr. Kresa continued, “Michael demonstrated deep commercial expertise in his prior role as MannKind’s Chief Commercial Officer as he built the capabilities from the bottom-up necessary to position Afrezza and the company for future growth.
---------- Do you guys think this was planned or just written to sound like it? I might have missed some posts:-) Been real busy on Twitter...
|
|
|
Post by falconquest on May 31, 2017 16:44:02 GMT -5
Matt successfully set the foundation for the company during its transition into a commercial entity and effectively prepared Michael to be his successor.” Mr. Kresa continued, “Michael demonstrated deep commercial expertise in his prior role as MannKind’s Chief Commercial Officer as he built the capabilities from the bottom-up necessary to position Afrezza and the company for future growth. ---------- Do you guys think this was planned or just written to sound like it? I might have missed some posts:-) Been real busy on Twitter... That's a tough one......"effectively prepared Michael to be his successor.” this statement sounds like it was planned but was the preparation through mutual collaboration or was it through argumentation over the proper direction which would cause Mike to develop a forward plan on his own? One cannot tell. I would like to think it is the former and that Matt has just been worn down and wanted out. I really don't see Matt as the kind of guy that would give up however. "as he built the capabilities from the bottom-up necessary to position Afrezza and the company for future growth." This sounds like he developed his own market strategy to me and let's face it, the reason Matt hired Mike is because Matt is a numbers guy and not a Marketing Specialist. We can't really know what the real story is, all we can do is speculate........like most things with Mannkind.
|
|